Comparative Pharmacology
Head-to-head clinical analysis: BRISTAMYCIN versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAMYCIN versus ERYC 125.
BRISTAMYCIN vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for CrCl <30 mL/min).
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic